Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis.

Mark J C Nuijten1, John Hutton

  • 1MEDTAP International, Dorpsstraat 75, 1546 LG Jisp, Amsterdam, Netherlands. nuijten@medtap.nl

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|March 5, 2002
PubMed
Summary

Preventive treatment with interferon beta for multiple sclerosis (MS) increases costs and quality-adjusted life years (QALYs). The health-economic justification for this MS treatment is questionable despite improved effectiveness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of Literacy and Developmental Screening of Preschool-Aged Children During Primary Care.

Pediatrics·2025
Same author

Functional connectivity of sensory and executive function networks during a story listening task is related to parent/child interaction during joint reading: a functional MRI diffusion map study.

Brain imaging and behavior·2025
Same author

A Primary Care-Based Approach to Improving Kindergarten Readiness.

Pediatrics·2025
Same author

A greater modulation of the visual and fronto-parietal networks for children in a post-media versus pre-media exposure group.

Acta paediatrica (Oslo, Norway : 1992)·2024
Same author

Student use of common online resources in a multi-campus medical school.

MedEdPublish (2016)·2024
Same author

Executive functions abilities in preschool-age children are negatively related to parental EF, screen-time and positively related to home literacy environment: an EEG study.

Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence·2023

Area of Science:

  • Health Economics
  • Neurology
  • Pharmacoeconomics

Background:

  • Multiple Sclerosis (MS) is a chronic neurological condition.
  • Preventive treatments aim to manage disease progression and improve patient outcomes.
  • Understanding the economic implications of MS treatments is crucial for healthcare systems.

Purpose of the Study:

  • To evaluate the cost-effectiveness of using interferon beta (IFNB) as a preventive treatment for multiple sclerosis compared to no preventive treatment.
  • To model the long-term costs and quality-adjusted life years (QALYs) associated with IFNB treatment in MS patients.

Main Methods:

  • A lifetime Markov process model was developed using data from published literature and clinical trials.
  • The model simulated costs and QALYs for patients receiving IFNB versus those not receiving preventive treatment.

Related Experiment Videos

  • The analysis was conducted from the perspective of the UK National Health Service (NHS).

    • Main Results:

    • Interferon beta preventive treatment increased average discounted costs from £51,214 to £221,436 per patient.
    • Undiscounted effectiveness increased from 24.9 to 28.2 QALYs.
    • The incremental cost-effectiveness ratio (ICER) was calculated at £51,582 per QALY, with sensitivity analyses supporting model robustness for other interferons.

    Conclusions:

    • Preventive interferon beta treatment for MS offers improved effectiveness but may not be fully justifiable from a health-economic standpoint.
    • The findings suggest a need for careful consideration of the cost-benefit balance for IFNB in MS management.
    • Further economic evaluations may be warranted to refine the understanding of IFNB's value in different MS populations.